Randomized trial · people
SS-31: no 12-week benefit, walk gains by 36 weeks open-label
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In Barth syndrome, elamipretide showed no clear benefit over placebo at 12 weeks; the walking and symptom gains seen with longer use come from an uncontrolled extension in a handful of patients.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 12
- Published
- 2021
- Journal
- Genet Med
What they tested
The team tested whether daily elamipretide improves walking ability and symptoms in people with Barth syndrome, an inherited disorder in which TAZ gene defects leave cardiolipin, a fat in the inner membrane of mitochondria, abnormal.
How the study was done
A randomized, double-blind, placebo-controlled crossover trial in 12 people with Barth syndrome. Each got 40 mg per day of elamipretide or placebo (a dummy treatment) for 12 weeks, then a 4-week break, then 12 weeks on the other option. Ten then went on to an open-label extension, where everyone knowingly got 40 mg per day of elamipretide, and not all of them reached 36 weeks.

What they found
In the placebo-controlled crossover part, elamipretide did not meet either main goal: better distance on the 6-minute walk test or a better score on a Barth syndrome symptom scale. By 36 weeks of the open-label extension, 6-minute walk distance had gone up by 95.9 m (p = 0.024) and the symptom score had dropped by 2.1 points (p = 0.031), a change toward fewer symptoms. Knee extensor strength, patients' overall impression of their symptoms, and some cardiac measures also improved significantly.
What it doesn’t show
The gains came only in the open-label extension, which had no placebo group, so they can't be separated from other causes. The trial was very small, and even fewer people stayed on through 36 weeks.
The paper
Reid Thompson et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.